Business Wire

PROJECT44

12.2.2020 09:02:16 CET | Business Wire | Press release

Share
project44 Continues Global Expansion with Significant Growth in Europe

project44, the global leader in advanced visibility for shippers and logistics service providers, has experienced significant growth across Europe following several recent announcements, including opening an office in Paris , adding several new team members , and building partnerships with global technology leaders .

Since acquiring Europe’s leading visibility provider, GateHouse Logistics, in 2018, project44 has increased global growth reaching more than 300 enterprise customers with over 20% in Europe, including leading brands such as Amazon, Coop, and Yazaki.

“With an increased need for real-time data and visibility across the entire supply chain, shippers and logistics service providers need a single global provider,” said Michael Gross, Director IT, Supply Chain and Logistics at Yazaki. “We’re excited for project44’s network to grow in Europe and beyond. Their plans for expansion are critical for supporting our global supply chain.”

With coverage in about 50 countries, integrations with over 760 telematics providers, and partnerships with global technology leaders such as SAP, project44 enables customers to tap into the most extensive visibility network across North America and Europe. With European carrier onboarding available in 16 languages and applications in 14 languages, p44’s comprehensive support ensures customers see the ROI of visibility in the fastest way possible.

To accelerate this European growth, project44 opened a Paris office in December of 2019 and has since retained several key hires for continued European expansion, reaching over 80 European-based employees in Aalborg, Amsterdam, Frankfurt, and Milan.

New team members include Regional VP of Sales Mickael Devena , Value Engineering Director Jatin Garg , Head of European Marketing Lorenzo Stranges, and Strategic Account Director Marco Tarpi . Devena and Garg bring extensive experience in transportation visibility from their time at Shippeo, while Stranges and Tarpi come from global SaaS leaders, including DocuSign and IBM respectively.

Michel Stekelenburg will also join the team as the Strategic Account Director for the Benelux region. In addition to several roles in supply chain technology, Stekelenburg serves as the President of the Benelux Roundtable for the Council of Supply Chain Management Professionals (CSCMP).

To lead this growing team, project44 has promoted Executive Vice President of Operations, Jørgen B Nielsen, to General Manager of Europe. With more than 20 years of experience with technical challenges and project execution in IT and telecom, Jørgen led GateHouse Logistics through rapid growth as Chief Operating Officer.

“Building on the GateHouse Logistics’s decade of significant success and expertise, project44 has continued to expand the European visibility market, delivering a seamless product and experience for our global customers,” said Jørgen. “As supply chains increase logistics and transportation operations across geographies, project44 will continue to expand globally and provide the coverage our customers need to effectively run their businesses.”

With over $110 million USD in capital, project44 will continue to explore additional international growth to deliver a seamless transportation visibility offering for global supply chains. By partnering with leading global carriers, project44 has already started gaining coverage beyond North America and Europe in Turkey, Russia, Ukraine, and Belarus. The visibility provider will also begin extending tracking connections in Morocco.

About project44

project44 is the world’s leading advanced visibility platform for shippers and logistics service providers. project44 connects, automates and provides visibility into key transportation processes to accelerate insights and shorten the time it takes to turn those insights into actions. Leveraging the power of the project44 cloud-based platform, organizations are able to increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional Amazon-like experience to their customers. Connected to thousands of carriers worldwide and having comprehensive coverage for all ELD and telematics devices on the market, project44 supports all transportation modes and shipping types, including Parcel, Final-Mile, Less-than-Truckload, Volume Less-than-Truckload, Truckload, Rail, Intermodal, and Ocean. To learn more, visit www.project44.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye